WO1992017218A1 - Vaisseau sanguin artificiel et composite - Google Patents
Vaisseau sanguin artificiel et composite Download PDFInfo
- Publication number
- WO1992017218A1 WO1992017218A1 PCT/JP1992/000373 JP9200373W WO9217218A1 WO 1992017218 A1 WO1992017218 A1 WO 1992017218A1 JP 9200373 W JP9200373 W JP 9200373W WO 9217218 A1 WO9217218 A1 WO 9217218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood vessel
- artificial blood
- group
- protein
- synthetic polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
Definitions
- the present invention relates to an artificial blood vessel used for treating diseases such as aorta, coronary arteries, and peripheral blood vessels.
- EPTFE polytetrafluoroethylene
- EPTFE does not have sufficient antithrombotic properties, and a sufficient patency rate can be obtained for artificial blood vessels with an inner diameter of 6 ⁇ or less, especially with an inner diameter of 4 mm or less.
- the following methods have been used to improve the antithrombotic properties of the material itself: (2) Immediately after transplanting the artificial blood vessel, the living tissue is induced to induce intimal formation to induce intimal formation. 3 a method of seeding vascular endothelial cells with excellent antithrombotic properties on the inner surface of an artificial blood vessel.
- the patency rate decreases due to thickening or exfoliation of the formed intima over a long period of time, and thus does not have sufficient performance as an artificial blood vessel.
- a method of seeding vascular endothelial cells on the inner surface of an artificial blood vessel has been studied (Takagi et al., Artificial Organs, 17, 679 ('88)); Gazettes). However, it takes a long time to collect and culture endothelial cells, and thus lacks immediacy. In addition, the engraftment and function of seeded endothelium are difficult, and a good patency rate has not been obtained.
- the intima is formed promptly after transplantation, and the formed intima is stably present for a long period of time, giving good patency.
- An artificial blood vessel covalently bound with a protein or peptide having the following characteristics (hereinafter referred to as a biofunctional substance) has excellent patency in the early stage of transplantation, and also has an intima formed rapidly, and this intima thickens over a long period of time.
- the present invention was found to exist stably without peeling or peeling, and to provide good patency, leading to completion of the present invention.
- the present invention provides an artificial blood vessel in which a protein or a peptide having a cell-adhering and growth action is covalently bonded to the surface of a tube made of a porous synthetic polymer via a hydroxyl group, a carboxyl group, an epoxy group or an amino group.
- a protein or a peptide having a cell-adhering and growth action is covalently bonded to the surface of a tube made of a porous synthetic polymer via a hydroxyl group, a carboxyl group, an epoxy group or an amino group.
- FIG. 1 shows a scanning electron micrograph of the inner surface of the artificial blood vessel of Example 1 in which gelatinized atelocollagen was chemically bonded to EPTFE according to the present invention. It is.
- FIG. 2 is a scanning electron micrograph of the inner surface of a vascular prosthesis of Comparative Example 2 in which gelatinized atelocollagen was applied to EPTFE and then crosslinked with glutaraldehyde as in the prior art.
- FIG. 3 is a scanning electron micrograph of the inner surface of the untreated EPTF E vascular prosthesis of Comparative Example 1.
- the porous synthetic polymer material used for the artificial blood vessel of the present invention has a large and medium diameter because it has the necessary strength as an artificial blood vessel, does not degrade and degrade in vivo, and has no toxicity.
- Polyester woven or knitted fabric that has been used as an artificial blood vessel, or E PTFE tubing is desirable.
- E PTFE tubing which has a microporous structure consisting of fibers and nodules, has a high porosity, and has excellent compatibility with living tissue, is most desirable.
- the porosity of the porous synthetic polymer material is 50% or more, preferably 70%. It is desirable that this is the case.
- the pore diameter of the porous material is preferably 2 nm or more, and particularly preferably 20 to 200 Am for EPTFE.
- the ratio of the area of the synthetic polymer material to the luminal surface of the artificial blood vessel in contact with the blood flow is 15 to 80%, and preferably 25 to 55%. This area ratio can be determined by scanning electron microscope observation. If the area ratio of the synthetic polymer material is too high, the contact area between the immobilized protein or peptide and blood becomes large, and the thrombus formation property is increased, so that the initial patency rate is reduced. On the other hand, if the ratio of the area occupied by the synthetic polymer material is too low, the effect of promoting the inner membrane formation by the immobilized protein or peptide cannot be sufficiently obtained.
- a chemical treatment is used as a method for introducing a functional group on the surface of a synthetic polymer material.
- the method may be a method based on physical treatment, such as radiation treatment such as radiation or electron beam irradiation, corona discharge, or glow discharge treatment.
- the treatment may be performed by a method suitable for each high molecular material.
- PET polyethylene terephthalate
- an ester bond is hydrolyzed by an acid or alcohol to form a carboxyl group, and then the ester group, hydroxyl group, What is necessary is just to convert into a amino group or an epoxy group.
- the graft polymerization may be performed by ultraviolet irradiation and corona discharge treatment.
- EPTFE after defluoridation using an alkali metal compound, a compound having a carboxyl group, hydroxyl group, amino group, amino acid group, etc. in the molecule is added to introduce these functional groups. be able to.
- alkali metal compound examples include methyllithium, n-butyllithium, t-butyllithium, sodium-naphthalene, naphthalene-benzophenone, and vinyllithium. Is used as a solution. Since sodium-naphthalene and sodium-benzophenone form a black-brown layer on the surface of EPTFE by the treatment, and it is difficult to uniformly treat the inside of the porous EPTFE, the present invention It is desirable to use methyllithium, n-butyllithium, and t-butyllithium in order to prepare the artificial blood vessel.
- Methyllithium, n-butyllithium, and t_butyllithium are themselves weak in extracting fluorine, so chelating reagents such as hexamethylphosphoric triamide ⁇ , N, N, N, N— It is necessary to add tetramethylethylenediamine and the like.
- Examples of substances having a hydroxyl group, a carboxyl group, an epoxy group or an amino group in a molecule include glycerol (meth) acrylate, 2-hydroxyxethyl (meth) acrylate, and 2-hydroxypropyl (meth) acrylate. Evening) acrylate, poly (ethylene glycol) (meth) acrylate, glycidyl (meth) acrylate, (meth) atalylic acid, arylamin, 2-aminoethyl (meth) acrylate Relate, Atarylamide, etc. Is raised. Further, an acid anhydride such as maleic anhydride may be added, followed by hydrolysis.
- an acid anhydride such as maleic anhydride may be added, followed by hydrolysis.
- an EPTFE tube is immersed in a methyllithium dimethyl ether solution under a nitrogen atmosphere, and hexamethylphosphoric triamide is added thereto and the mixture is heated at 0 ° C. After leaving it for 30 minutes to extract the fluorine atoms of EPTFE, the reaction solution was removed, and a solution of acrylic acid in tetrahydrofuran was added thereto. Incubate with C for 10 hours. After the reaction, excess acrylic acid or a polymer thereof can be washed and removed to obtain a graft form of acrylic acid.
- a method suitable for each substance may be selected. What is necessary is to select and fix the existing bond without losing the inducing action and without decomposing in time until the formation of the inner membrane.
- a covalent bond is formed by a dehydration condensation with respect to a hydroxyl group, a carboxy group and an amino group, and by an addition reaction with a epoxide group.
- the hydroxyl group may be directly bonded to the hydroxyl group by dehydration condensation using a carposimide as a catalyst, or after increasing the reactivity by introducing a leaving group such as a trifluoromethanesulfonyl group into the hydroxyl group.
- the carboxyl group may be directly bonded using a dehydration condensation catalyst such as carbodiimide, or may be reacted with N-hydroxysuccinimide to introduce an active ester to increase the reactivity. After that, it may be reacted with the amino acid of the protein.
- the surface coated and cross-linked as in the past has irregularities of several meters or more, and it is difficult to completely cover the surface of the porous synthetic polymer material. The unevenness of the surface is 50 or less, and the inside of the porous material is completely covered.
- the proteins to be complexed include cell adhesion proteins, endothelial cell growth factor, and vascular growth factor. Among them, collagen, gelatin, albumin, laminin, and fibronectin are excellent.
- the composite vascular prosthesis of the present invention is obtained by chemically fixing a protein or a peptide having cell adhesion or cell growth action to the surface of a porous synthetic polymer material, particularly preferably EPTF. All over the wall It is only about a submicron thick and is tightly covered by covalent bonds.
- the unevenness of the composite surface is 5 Omn or less, and a tissue inducing action can be imparted to the surface without substantially changing the shape of the porous synthetic polymer.
- the shape since it is thinly compounded only on the surface of the porous polymer, the shape does not change due to the compounding.Therefore, depending on the porous structure of the synthetic polymer material, the immobilized area and amount of protein and peptide can be reduced. Can be controlled.
- the protein and the peptide may be peeled off by handling during operation or the like. Absent.
- the surface irregularities are as small as 5 O nm or less, and thrombus is not induced by blood rheology by the irregularities generated by the complexation, and the patency rate immediately after transplantation does not decrease.
- the biological tissue inducing substance is thinly composited only on the surface of the porous synthetic polymer material, no protein or peptide exists in the porous void.
- the covering area of the protein or the peptide and the amount of the complex can be controlled, and as a result, the contact area between the protein and the blood can be changed.
- the complexed structure can be controlled while balancing both thrombus formation and intimal erectile erection.
- the composite artificial blood vessel since the biological tissue-inducing substance is composited over the entire inner surface of the porous wall, the composite artificial blood vessel has a high porosity and a porous structure. At the same time, biological tissue components invade quickly, and at the same time, extension of the intima from the anastomosis progresses very quickly. In addition, since it is firmly and uniformly fixed by a covalent bond, the formed inner film can be stably present for a long period of time without peeling.
- Average fiber length 30 ⁇ ⁇ Porosity 7 2%, resin surface occupied in lumen area An EPTFE tube with a volume ratio of 45%, an inner diameter of 1.5 mm, an outer diameter of 2.5 mm, and a length of 10 was placed in a nitrogen atmosphere of methyllithium at 0 ° C in a nitrogen atmosphere (1.4 M). After immersion in a mixed solution of 2 ml of 2 ml of hesamethylphosphoric triamide for 30 minutes, only the solution was removed, and a solution of lg acrylate in 2 ml of tetrahydrofuran was added. The reaction was performed at ° C for 10 hours.
- the graft volume of acrylic acid was 45 per cm of tube.
- GAC gelatinized atherocollagen
- the amount of bound GAC was 55 g / cm tube.
- This artificial blood vessel has a tensile strength of 3.2 kg and a suture strength (a load that causes tearing when pulled through a 0.2 mm ⁇ wire at 3 mm from the end of the tube). Compared to 3.3 kg and 150 g of the blood vessel, there was almost no decrease, and it had sufficient strength for practical use as a human blood vessel.
- EPTFE tube with average fiber length of 30 ⁇ m, porosity of 72%, area ratio of resin to lumen area of 45%, inner diameter of 2.0 mm. Outer diameter of 3.0 mm, length of 20 mm , 0.
- a solution of lg acrylate in 20 ml of tetrahydrofuran was added, and the mixture was reacted at 60 ° C. for 10 hours. Thereafter, unreacted acrylic acid and polymerized acrylic acid were washed away to obtain an acrylic acid graft.
- the graft amount of acrylic acid was 45 g / cm tube.
- 2-Hydroxyshetyl acrylate was graphed in the same manner as in Example 2 in the same EPTFE tube.
- the amount of grafting was 65 g / cm of tube.
- This tube is immersed in a solution of 2,2,2-trifluorenesulfonic acid (1 ml) and triethylamine (1 ml) in dimethyl ether (20 ml), and reacted at room temperature for 4 hours to react with 2,2,2- Trifluoroethanesulfonyl group was introduced.
- fibronectin derived from bovine plasma, manufactured by B-Ham
- the amount of bound fibrous nectin was 40 ⁇ g / cm tube.
- the microstructure of the FE fiber due to one fiber knot was completely maintained, and the unevenness of the composited surface was 1 Onm or less, and no large unevenness as observed in the case of the coating composite was observed.
- the composited GAC did not peel off due to handling such as bending. .
- the patency rate did not decrease much after one year, and the patency rate was 83%.
- the formed endothelium was stable, and no adhesion of thrombus was observed.
- Example 4 Average pore diameter 60 m, porosity 60%, resin area occupies 50% of lumen area, inner diameter 2.0 dragon, outer suspicion 3.0 mm, length 20 mm Polyester knit tube is hydrolyzed with 6 N hydrochloric acid To form a carbo-oxyl group.
- GAC gelatinized atherocollagen
- Example 1 Six E PTF E tubes as in Example 1 were implanted into the abdominal aorta of one rat. Three weeks later, the patency rate was 100%, but few biological tissue components such as fibroblasts penetrated into the porous wall of the vascular prosthesis, and the endothelial coverage of the luminal surface was 50%. It was low. One year later, the patency rate has dropped to 67%, and partial stenosis has occurred even in patency cases. It had occurred.
- Example 2 The same 0.3% GAC solution as in Example 1 was vacuum-injected from the inside of the same EPTFE tube as in Example 1, crosslinked with glutaraldehyde, and dried.
- the composite amount of GAC was 0.2 mgZcm.
- the composite GAC partially formed a film between the fibers of the EPT FE, and the surface had irregularities of 0.5 to 1 ⁇ m. Had been formed. In addition, there were some areas where GAC was not applied. Repeated bending of this composite vascular prosthesis with a radius of curvature of 5 nun or less facilitated the GAC exfoliation.
- Example 2 The same 0.3% GAC solution as in Example 1 was vacuum-injected from the inside of the same E PTF E tube as in Example 2, crosslinked with glutaraldehyde, and dried.
- the composite amount of GAC was 0.3 mgZcm.
- the composite GAC partially formed a film between the fibers of E PTF E, and the surface had irregularities of 0.5 to 1 im. It had been. In addition, there were some areas where GAC was not applied.
- This composite vascular graft has a radius of curvature of 5 mm When the following bending was repeated, the GAC was easily peeled.
- FIG. 1 is a scanning electron micrograph of the inner surface of the artificial blood vessel of Example 1 in which gelatinized atelocollagen was chemically bonded to EPTF E according to the present invention.
- FIG. 2 is a scanning electron micrograph of the inner surface of a vascular prosthesis of Comparative Example 2 in which gelatinized atelocollagen was applied to EPTFE and then cross-linked with darthal aldehyde as in the prior art.
- FIG. 3 is a scanning electron micrograph of the inner surface of the untreated EPTF E vascular prosthesis of Comparative Example 1.
- gelatinized atelocollagen is thinly and uniformly complexed, and the shape of EPTFE is completely retained, whereas the conventional method has irregularities of several meters.
- the invention's effect As described above, in the composite artificial blood vessel of the present invention, a substance having a biological tissue inducing action is uniformly composited stably on the surface without changing the shape of the porous synthetic polymer material by covalent bonds. . Therefore, the synergistic effect of the porous structure with the porous structure of EPTFE, in particular, makes it possible to form the inner membrane quickly without inducing primary thrombus and to stably maintain it over a long period of time. It is possible.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69229312T DE69229312T2 (de) | 1991-03-29 | 1992-03-27 | Künstliches blutgefäss aus komposit-material |
AU14470/92A AU652236B2 (en) | 1991-03-29 | 1992-03-27 | Composite artificial blood vessel |
CA002084057A CA2084057C (en) | 1991-03-29 | 1992-03-27 | Composite artificial blood vessel |
EP92907616A EP0531547B1 (en) | 1991-03-29 | 1992-03-27 | Composite artificial blood vessel |
US08/347,156 US5591225A (en) | 1991-03-29 | 1994-11-23 | Composite artificial blood vessel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/66070 | 1991-03-29 | ||
JP6607091 | 1991-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992017218A1 true WO1992017218A1 (fr) | 1992-10-15 |
Family
ID=13305217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000373 WO1992017218A1 (fr) | 1991-03-29 | 1992-03-27 | Vaisseau sanguin artificiel et composite |
Country Status (8)
Country | Link |
---|---|
US (1) | US5591225A (ja) |
EP (1) | EP0531547B1 (ja) |
JP (1) | JP2815752B2 (ja) |
AT (1) | ATE180681T1 (ja) |
AU (1) | AU652236B2 (ja) |
CA (1) | CA2084057C (ja) |
DE (1) | DE69229312T2 (ja) |
WO (1) | WO1992017218A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996037165A1 (en) * | 1995-05-26 | 1996-11-28 | Bsi Corporation | Method and implantable article for promoting endothelialization |
US6053939A (en) * | 1996-02-15 | 2000-04-25 | Vascular Graft Research Center Co., Ltd. | Artificial blood vessel |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0767895A (ja) * | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | 抗菌性人工血管及び抗菌性手術用縫合糸 |
EP0741585A1 (en) * | 1994-01-21 | 1996-11-13 | Brown University Research Foundation | Biocompatible implants |
JPH07250887A (ja) * | 1994-03-15 | 1995-10-03 | Seikagaku Kogyo Co Ltd | 人工血管およびその製造方法 |
WO1995029713A1 (en) * | 1994-04-29 | 1995-11-09 | W.L. Gore & Associates, Inc. | Improved blood contact surfaces using endothelium on a subendothelial extracellular matrix |
US5716394A (en) * | 1994-04-29 | 1998-02-10 | W. L. Gore & Associates, Inc. | Blood contact surfaces using extracellular matrix synthesized in vitro |
US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
DE19505070C2 (de) * | 1995-02-15 | 1997-03-27 | Axel Prof Dr Med Haverich | Künstliche Gefäßsysteme und Verfahren zu ihrer Herstellung |
AUPN174495A0 (en) * | 1995-03-15 | 1995-04-06 | Ketharanathan, Vettivetpillai | Surgical prostheses |
JP3799626B2 (ja) * | 1995-04-25 | 2006-07-19 | 有限会社ナイセム | 心臓血管修復材及びその製造方法 |
AU5391996A (en) * | 1995-06-07 | 1996-12-30 | W.L. Gore & Associates, Inc. | Bioabsorbable space filling soft tissue prosthesis |
US5874165A (en) * | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
US5914182A (en) * | 1996-06-03 | 1999-06-22 | Gore Hybrid Technologies, Inc. | Materials and methods for the immobilization of bioactive species onto polymeric substrates |
AU8017498A (en) * | 1997-05-16 | 1998-12-11 | Commonwealth Scientific And Industrial Research Organisation | Collagen-like polymers with cell binding activity |
US6290718B1 (en) | 1998-02-02 | 2001-09-18 | Regeneration Technologies, Inc. | Luminal graft, stent or conduit made of cortical bone |
US6129757A (en) | 1998-05-18 | 2000-10-10 | Scimed Life Systems | Implantable members for receiving therapeutically useful compositions |
FI981257A (fi) * | 1998-06-03 | 1999-12-04 | Salonen Eeva Marjatta | Tukkeutumista estävien aineiden käyttö ja menetelmä lääketieteellisten tuuletusputkien tukkeutumisen estämiseksi |
US6106555A (en) * | 1998-12-15 | 2000-08-22 | Av Healing Llc | Method for tissue fixation |
US6689160B1 (en) * | 1999-05-31 | 2004-02-10 | Sumitomo Electric Industries, Ltd. | Prosthesis for blood vessel |
AU2002241676B2 (en) * | 2001-12-21 | 2008-10-23 | Nfocus Neuromedical, Inc. | Composite stent with polymeric covering and bioactive coating |
KR100496354B1 (ko) * | 2002-03-27 | 2005-06-20 | 서울산업대학교 산학협력단 | 생분해성 고분자 지지체층을 포함하는 하이브리드인공혈관 및 그의 제조 방법 |
EP1605865B1 (en) * | 2003-03-17 | 2008-12-10 | ev3 Endovascular, Inc. | Stent with thin film composite laminate |
US7338517B2 (en) * | 2003-06-04 | 2008-03-04 | University Of South Carolina | Tissue scaffold having aligned fibrils and artificial tissue comprising the same |
US7198855B2 (en) * | 2003-09-12 | 2007-04-03 | Becton, Dickinson And Company | Methods of surface modification of a flexible substrate to enhance cell adhesion |
US8617234B2 (en) * | 2004-05-25 | 2013-12-31 | Covidien Lp | Flexible vascular occluding device |
US8267985B2 (en) | 2005-05-25 | 2012-09-18 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
AU2005247490B2 (en) | 2004-05-25 | 2011-05-19 | Covidien Lp | Flexible vascular occluding device |
US20060206200A1 (en) | 2004-05-25 | 2006-09-14 | Chestnut Medical Technologies, Inc. | Flexible vascular occluding device |
US8623067B2 (en) | 2004-05-25 | 2014-01-07 | Covidien Lp | Methods and apparatus for luminal stenting |
AU2010236494B2 (en) | 2004-05-25 | 2013-05-30 | Covidien Lp | Vascular stenting for aneurysms |
US20060184236A1 (en) * | 2005-02-11 | 2006-08-17 | Medtronic Vascular, Inc. | Intraluminal device including an optimal drug release profile, and method of manufacturing the same |
JP2008531125A (ja) * | 2005-02-23 | 2008-08-14 | サーモディクス,インコーポレイティド | ラミニンコーティングを有する移植可能な医療装置、及び使用方法 |
US8273101B2 (en) | 2005-05-25 | 2012-09-25 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
JP4945714B2 (ja) | 2005-05-25 | 2012-06-06 | タイコ ヘルスケア グループ リミテッド パートナーシップ | 管路内に閉塞装置を供給して展開するためのシステム及び方法 |
US20080317814A1 (en) * | 2005-11-17 | 2008-12-25 | Access Plus Co., Ltd. | Tube for Connecting Marteriovenous and Interposition for Medical Operation |
US8152833B2 (en) | 2006-02-22 | 2012-04-10 | Tyco Healthcare Group Lp | Embolic protection systems having radiopaque filter mesh |
WO2008072378A1 (ja) * | 2006-12-13 | 2008-06-19 | Fujifilm Corporation | 合成高分子表面の生体高分子によるコーティング方法 |
WO2009140437A1 (en) | 2008-05-13 | 2009-11-19 | Nfocus Neuromedical, Inc. | Braid implant delivery systems |
US20100114293A1 (en) * | 2008-10-31 | 2010-05-06 | Vioptix, Inc. | Multibranch Vessel Extender |
US20100114292A1 (en) * | 2008-10-31 | 2010-05-06 | Vioptix, Inc. | Vessel Extender |
US9155647B2 (en) | 2012-07-18 | 2015-10-13 | Covidien Lp | Methods and apparatus for luminal stenting |
US9301831B2 (en) | 2012-10-30 | 2016-04-05 | Covidien Lp | Methods for attaining a predetermined porosity of a vascular device |
US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9943427B2 (en) | 2012-11-06 | 2018-04-17 | Covidien Lp | Shaped occluding devices and methods of using the same |
US9157174B2 (en) | 2013-02-05 | 2015-10-13 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9320592B2 (en) | 2013-03-15 | 2016-04-26 | Covidien Lp | Coated medical devices and methods of making and using same |
US9545301B2 (en) | 2013-03-15 | 2017-01-17 | Covidien Lp | Coated medical devices and methods of making and using same |
US9668890B2 (en) | 2013-11-22 | 2017-06-06 | Covidien Lp | Anti-thrombogenic medical devices and methods |
US9789228B2 (en) | 2014-12-11 | 2017-10-17 | Covidien Lp | Antimicrobial coatings for medical devices and processes for preparing such coatings |
US10451637B2 (en) * | 2017-03-24 | 2019-10-22 | The University Of British Columbia | Synthetic blood vessels and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034450A (ja) * | 1983-08-03 | 1985-02-22 | テルモ株式会社 | 人工血管 |
JPS61135651A (ja) * | 1984-11-30 | 1986-06-23 | バスカテツク リミテツド | 移植用血管組織片及びその製造方法 |
JPS62152469A (ja) * | 1985-12-24 | 1987-07-07 | 住友電気工業株式会社 | 複合構造管状臓器補綴物 |
JPS62152468A (ja) * | 1985-12-24 | 1987-07-07 | 住友電気工業株式会社 | 複合構造管状臓器補綴物 |
JPS62258666A (ja) * | 1986-03-12 | 1987-11-11 | ベーブラウン―エスエスツェー アーゲー | 架橋ゼラチン含浸人工血管およびその製法 |
JPS6346169A (ja) * | 1986-04-07 | 1988-02-27 | 工業技術院長 | 抗血栓性材料 |
JPH01170467A (ja) * | 1987-12-24 | 1989-07-05 | Toray Ind Inc | 血管代替材料 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5239838Y2 (ja) * | 1972-11-07 | 1977-09-08 | ||
US4208745A (en) * | 1976-01-21 | 1980-06-24 | Sumitomo Electric Industries, Ltd. | Vascular prostheses composed of polytetrafluoroethylene and process for their production |
JPS57115250A (en) * | 1981-01-09 | 1982-07-17 | Unitika Ltd | Tubular artificial organ |
US4960423A (en) * | 1982-11-17 | 1990-10-02 | Smith Donald W | Method of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics |
US4510094A (en) * | 1983-12-06 | 1985-04-09 | Minnesota Mining And Manufacturing Company | Platinum complex |
CA1292597C (en) * | 1985-12-24 | 1991-12-03 | Koichi Okita | Tubular prothesis having a composite structure |
EP0241838B1 (en) * | 1986-04-07 | 1992-04-15 | Agency Of Industrial Science And Technology | Antithrombogenic material |
EP0246638A3 (en) * | 1986-05-23 | 1989-03-15 | Cordis Corporation | Biologically modified synthetic grafts |
US5338770A (en) * | 1988-06-08 | 1994-08-16 | Cardiopulmonics, Inc. | Gas permeable thrombo-resistant coatings and methods of manufacture |
US5126140A (en) * | 1988-08-03 | 1992-06-30 | New England Deaconess Hospital Corporation | Thrombomodulin-coated bicompatible substance |
US5167960A (en) * | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
JPH0382472A (ja) * | 1989-08-28 | 1991-04-08 | Terumo Corp | 生体内長期埋植材及びその製造方法 |
US5118524A (en) * | 1990-09-14 | 1992-06-02 | The Toronto Hospital | Vascular biomaterial |
-
1992
- 1992-03-27 AU AU14470/92A patent/AU652236B2/en not_active Ceased
- 1992-03-27 JP JP4070824A patent/JP2815752B2/ja not_active Expired - Fee Related
- 1992-03-27 AT AT92907616T patent/ATE180681T1/de not_active IP Right Cessation
- 1992-03-27 EP EP92907616A patent/EP0531547B1/en not_active Expired - Lifetime
- 1992-03-27 DE DE69229312T patent/DE69229312T2/de not_active Expired - Fee Related
- 1992-03-27 WO PCT/JP1992/000373 patent/WO1992017218A1/ja active IP Right Grant
- 1992-03-27 CA CA002084057A patent/CA2084057C/en not_active Expired - Fee Related
-
1994
- 1994-11-23 US US08/347,156 patent/US5591225A/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034450A (ja) * | 1983-08-03 | 1985-02-22 | テルモ株式会社 | 人工血管 |
JPS61135651A (ja) * | 1984-11-30 | 1986-06-23 | バスカテツク リミテツド | 移植用血管組織片及びその製造方法 |
JPS62152469A (ja) * | 1985-12-24 | 1987-07-07 | 住友電気工業株式会社 | 複合構造管状臓器補綴物 |
JPS62152468A (ja) * | 1985-12-24 | 1987-07-07 | 住友電気工業株式会社 | 複合構造管状臓器補綴物 |
JPS62258666A (ja) * | 1986-03-12 | 1987-11-11 | ベーブラウン―エスエスツェー アーゲー | 架橋ゼラチン含浸人工血管およびその製法 |
JPS6346169A (ja) * | 1986-04-07 | 1988-02-27 | 工業技術院長 | 抗血栓性材料 |
JPH01170467A (ja) * | 1987-12-24 | 1989-07-05 | Toray Ind Inc | 血管代替材料 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996037165A1 (en) * | 1995-05-26 | 1996-11-28 | Bsi Corporation | Method and implantable article for promoting endothelialization |
US5744515A (en) * | 1995-05-26 | 1998-04-28 | Bsi Corporation | Method and implantable article for promoting endothelialization |
US6053939A (en) * | 1996-02-15 | 2000-04-25 | Vascular Graft Research Center Co., Ltd. | Artificial blood vessel |
Also Published As
Publication number | Publication date |
---|---|
EP0531547A4 (en) | 1993-08-04 |
AU652236B2 (en) | 1994-08-18 |
US5591225A (en) | 1997-01-07 |
EP0531547B1 (en) | 1999-06-02 |
AU1447092A (en) | 1992-11-02 |
DE69229312D1 (de) | 1999-07-08 |
CA2084057A1 (en) | 1992-09-30 |
EP0531547A1 (en) | 1993-03-17 |
DE69229312T2 (de) | 1999-11-04 |
JP2815752B2 (ja) | 1998-10-27 |
CA2084057C (en) | 1999-12-07 |
ATE180681T1 (de) | 1999-06-15 |
JPH05269198A (ja) | 1993-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992017218A1 (fr) | Vaisseau sanguin artificiel et composite | |
JP4526487B2 (ja) | ポリテトラフルオロエチレン製の埋め込み可能なチューブ状プロテーゼ | |
AU2002241676B2 (en) | Composite stent with polymeric covering and bioactive coating | |
US4594407A (en) | Prosthetic devices derived from krebs-cycle dicarboxylic acids and diols | |
US6053939A (en) | Artificial blood vessel | |
US4670286A (en) | Method of forming prosthetic devices | |
JP3318578B2 (ja) | 内皮化を促進するための方法及び移植用製品 | |
CA2066213A1 (en) | Surfaces having desirable cell adhesive effects | |
JPH0611305B2 (ja) | 抗血栓性材料の製造方法 | |
WO2018139665A1 (ja) | 血管内皮系細胞に特異的に結合するペプチドの使用、及びペプチド | |
Ramshaw et al. | Applications of collagen in medical devices | |
JP5028625B2 (ja) | 人工血管の製造方法 | |
JPH06504546A (ja) | 貯蔵製剤 | |
JPH04288165A (ja) | 器官移植物およびその製造方法 | |
JP2986728B2 (ja) | 人工血管 | |
JPH0732798B2 (ja) | 複合構造管状臓器補綴物 | |
JPH01170467A (ja) | 血管代替材料 | |
JPH09276395A (ja) | 人工血管 | |
JPH01170465A (ja) | 生体内インプラント材 | |
JP3014325B2 (ja) | 人工血管及びその製造方法 | |
JPH09327509A (ja) | 人工血管 | |
Ye et al. | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers | |
JPH0135666B2 (ja) | ||
JP2020065632A (ja) | 医療器具 | |
JPH03280960A (ja) | 人工補綴材およびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2084057 Country of ref document: CA Ref document number: 1992907616 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992907616 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992907616 Country of ref document: EP |